Insight Molecular Diagnostics Inc (NASDAQ: IMDX) open the trading on Thursday, with a bit cautious approach as it glided -6.25% to $2.85, before settling in for the price of $3.04 at the close. Taking a more long-term approach, IMDX posted a 52-week range of $1.92-$4.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 11.82% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 11.82%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 79.61%. This publicly-traded company’s shares outstanding now amounts to $28.60 million, simultaneously with a float of $20.06 million. The organization now has a market capitalization sitting at $81.51 million. At the time of writing, stock’s 50-day Moving Average stood at $3.06, while the 200-day Moving Average is $2.83.
Insight Molecular Diagnostics Inc (IMDX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Diagnostics & Research industry. Insight Molecular Diagnostics Inc’s current insider ownership accounts for 29.84%, in contrast to 56.35% institutional ownership. According to the most recent insider trade that took place on Feb 07 ’25, this organization’s Chief Financial Officer bought 97,561 shares at the rate of 2.05, making the entire transaction reach 200,000 in total value, affecting insider ownership by 151,231. Preceding that transaction, on Feb 07 ’25, Company’s 10% Owner bought 1,077,600 for 2.05, making the whole transaction’s value amount to 2,209,080. This particular insider is now the holder of 2,872,671 in total.
Insight Molecular Diagnostics Inc (IMDX) Earnings and Revenue Records
Insight Molecular Diagnostics Inc’s EPS increase for this current 12-month fiscal period is 79.61% and is forecasted to reach -0.94 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 43.74% through the next 5 years, which can be compared against the 11.82% growth it accomplished over the previous five years trading on the market.
Insight Molecular Diagnostics Inc (NASDAQ: IMDX) Trading Performance Indicators
Let’s observe the current performance indicators for Insight Molecular Diagnostics Inc (IMDX). It’s Quick Ratio in the last reported quarter now stands at 3.70. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 21.23.
In the same vein, IMDX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.53, a figure that is expected to reach -0.23 in the next quarter, and analysts are predicting that it will be -0.94 at the market close of one year from today.
Technical Analysis of Insight Molecular Diagnostics Inc (IMDX)
[Insight Molecular Diagnostics Inc, IMDX] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 9.59% While, its Average True Range was 0.33.
Raw Stochastic average of Insight Molecular Diagnostics Inc (IMDX) in the period of the previous 100 days is set at 31.73%, which indicates a major rise in contrast to 15.24% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 164.01% that was higher than 93.90% volatility it exhibited in the past 100-days period.
